Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Olimel N9E is a multi-chamber parenteral nutrition emulsion designed for intravenous administration. Developed by Baxter, it consists of three separate compartments containing a lipid emulsion (refined olive oil and refined soybean oil), an amino acid solution with electrolytes, and a glucose solution with calcium. The "N9" designation indicates a high nitrogen content (approximately 14.2 g/L), while the "E" signifies the inclusion of electrolytes. It is specifically formulated to meet the high protein requirements of patients, particularly those in the early phase of acute critical illness, while providing a balanced supply of energy and essential nutrients. Due to its high osmolarity (approximately 1500 mOsm/L), it is intended for administration via a central vein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Olimel N9E.